Emcure Pharmaceuticals Faces FDA Observations Post-Pune Facility Inspection

Emcure Pharmaceuticals announced that the US FDA issued two observations following an inspection at its Pune API manufacturing plant. The US health regulator conducted a cGMP inspection from February 19-25. The firm promises to address the issues outlined in Form 483 promptly.

Emcure Pharmaceuticals revealed on Wednesday that its active pharmaceutical ingredient (API) manufacturing facility in Pune has come under scrutiny. The US Food and Drug Administration (USFDA) issued two observations after inspecting the site.

The inspection, focused on current Good Manufacturing Practices (cGMP), was conducted from February 19 to 25. Upon its conclusion, Emcure received a Form 483 detailing the two observations made by the regulator.

The company assured stakeholders that it is actively working to address the findings and intends to provide a comprehensive response to the USFDA within the designated timeframe.